Browse MYL1

Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF13405 EF-hand domain
Function

Regulatory light chain of myosin. Does not bind calcium.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006936 muscle contraction
GO:0006941 striated muscle contraction
GO:0008015 blood circulation
GO:0030048 actin filament-based movement
GO:0030049 muscle filament sliding
GO:0033275 actin-myosin filament sliding
GO:0060047 heart contraction
GO:0060048 cardiac muscle contraction
GO:0070252 actin-mediated cell contraction
Molecular Function GO:0008307 structural constituent of muscle
Cellular Component GO:0005859 muscle myosin complex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016460 myosin II complex
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-397014: Muscle contraction
R-HSA-390522: Striated Muscle Contraction
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.940.168
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8760.438
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9880.301
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.9960.0459
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.3690.0931
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.5450.399
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.3270.149
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.170.925
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.7920.198
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.430.424
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.430.538
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1340.499
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYL1
Namemyosin, light chain 1, alkali; skeletal, fast
Aliases myosin, light polypeptide 1, alkali; skeletal, fast; MLC1F; MLC3F; A1 catalytic; A2 catalytic; MLC1/MLC3; ML ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.